Clinical trials: Alzheimer; Early Onset
Alzheimer Disease (AD)
Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease
This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease.
- Trial name
- NCT07554872
- Testing
- Neural Stem Cell-Derived Exosomes
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Mental Health Center
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA)
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease
- Trial name
- NCT02740634
- Testing
- F-18 AV 1451, C-11 PiB
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Alzheimer Disease, Early Onset
Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients
Current diagnosis of Alzheimer disease is made by clinical, neuropsychological, and neuroimaging assessments. Routine structural neuroimaging evaluation is based on nonspecific features, such as atrophy, which is a late feature…
- Trial name
- NCT00909285
- Testing
- TMS stimulation, Cognitive training
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Assaf-Harofeh Medical Center
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Engagement 2.0 Forms of Consent for Data (re-)Use
The objective of this qualitative study is to create a better understanding of patients' mental model of health data engagement interfaces and tools (such as Dynamic Consent).
- Trial name
- ENGAGE (NCT05229978)
- Testing
- Showing an existing Dynamic Consent (computer interface) as prompt
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Early Onset Alzheimer Disease
Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)
The purpose of this study is to evaluate the efficacy of NKO™ softgels in reducing decline of global cognitive function as measured by the Neuropsychological Test Battery (NTB), in patients diagnosed with early stage Alzheimer's…
- Trial name
- MNEMOSYNE (NCT00867828)
- Testing
- Neptune Krill Oil, Fish Oil
- Where
- 14 sites in Canada
- Volunteers
- 175 people
- Sponsor
- NeuroBioPharm Inc.
Frailty, Cognitive Impairment
A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty
Cognitive frailty, characterized by the coexistence of physical frailty and cognitive impairment, is a robust indicator of cognitive decline.
- Conditions
- Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild
- Trial name
- NCT05754021
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Baylor College of Medicine
Alzheimer Disease, Early Onset
Efavirenz for Patients With Alzheimer's Disease
This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early dementia due to Alzheimer's…
- Trial name
- EPAD (NCT03706885)
- Testing
- Sustiva Pill
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Western Reserve University
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour.
- Trial name
- PRImus-AD (NCT06182085)
- Testing
- PRI-002
- Where
- 38 sites in Czechia, Germany and 4 more
- Volunteers
- 304 people
- Sponsor
- PRInnovation GmbH
Early Onset Alzheimer Disease, Mild Cognitive Impairment
Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Establishment of a BNA reference database for the Adult and Elderly Population. Hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical…
- Conditions
- Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
- Trial name
- (BNA™) (NCT02875496)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd